Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Alnylam Pharmaceuticals (ALNY) Surpasses Q4 Earnings Estimates
10:11am, Thursday, 12'th Feb 2026
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $1.25 per share, beating the Zacks Consensus Estimate of $1.16 per share. This compares to earnings of $0.06 per share a year ago.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 12'th Feb 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and ful
Countdown to Alnylam (ALNY) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
10:17am, Monday, 09'th Feb 2026
Besides Wall Street's top-and-bottom-line estimates for Alnylam (ALNY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qua
Alnylam Pharmaceuticals (ALNY) Earnings Expected to Grow: Should You Buy?
11:01am, Thursday, 05'th Feb 2026
Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
08:00am, Thursday, 29'th Jan 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and
Should You Buy Alnylam Pharmaceuticals Before Feb. 12?
04:44am, Wednesday, 28'th Jan 2026
Alnylam will likely report strong sales growth for Amvuttra in its February quarterly update. Management should also provide news about the initiation of two clinical studies.
Strs Ohio Sells 2,155 Shares of Alnylam Pharmaceuticals, Inc. $ALNY
06:12am, Monday, 26'th Jan 2026
Strs Ohio cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 7.1% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commissi
Wealth Enhancement Advisory Services LLC Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY
05:36am, Monday, 26'th Jan 2026
Wealth Enhancement Advisory Services LLC grew its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by 183.8% during the third quarter, according to its most recent filing with the Secur
Essex LLC Sells 1 Shares of Alnylam Pharmaceuticals Inc (ALNY)
09:17am, Tuesday, 20'th Jan 2026
Summary Essex LLC reduced its stake in Alnylam Pharmaceuticals Inc (ALNY) by 0.18%, selling 1 shares and holding 546 shares valued at about $217,120 as
Allstate Corp Acquires Shares of 4,571 Alnylam Pharmaceuticals, Inc. $ALNY
04:19am, Tuesday, 20'th Jan 2026
Allstate Corp bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The
Donoghue Forlines LLC Takes $2.11 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY
06:14am, Sunday, 18'th Jan 2026
Donoghue Forlines LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) during the undefined quarter, according to the company in its most recent 13F filing with the Securities
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Recommendation of “Moderate Buy” from Analysts
03:48am, Thursday, 15'th Jan 2026
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twenty-seven ratings firms that are currently covering the firm, Marke
Alnylam Pharmaceuticals Unveils “Alnylam 2030” as Amvuttra Drives Breakout Growth at JPMorgan Conf.
02:02am, Wednesday, 14'th Jan 2026
Alnylam Pharmaceuticals (NASDAQ: ALNY) used its presentation at the JPMorgan Healthcare Conference to outline what CEO Yvonne Greenstreet called the company's "next exciting chapter," highlighting a b
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:16pm, Monday, 12'th Jan 2026
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale
01:33pm, Monday, 12'th Jan 2026
Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company's focus on scaling its operations.
